Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (1y) (2013 - 2026)
Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-14,223.53% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Enanta Pharmaceuticals |
365.48 Mn |
201.71 Mn |
- |
89.86% |
| Date | Value |
|---|
| Mar 31, 2026 |
89.86% |
| Dec 31, 2025 |
-89.09% |
| Sep 30, 2025 |
-958.30% |
| Jun 30, 2025 |
44.53% |
| Mar 31, 2025 |
-204.81% |
| Dec 31, 2024 |
203.65% |
| Sep 30, 2024 |
114.89% |
| Jun 30, 2024 |
-226.22% |
| Mar 31, 2024 |
-23.73% |
| Dec 31, 2023 |
-2,466.63% |
| Sep 30, 2023 |
-162.64% |
| Jun 30, 2023 |
337.52% |
| Mar 31, 2023 |
153.30% |
| Dec 31, 2022 |
-104.23% |
| Sep 30, 2022 |
-70.29% |
| Jun 30, 2022 |
87.23% |
| Mar 31, 2022 |
-363.62% |
| Dec 31, 2021 |
230.67% |
| Sep 30, 2021 |
513.43% |
| Jun 30, 2021 |
-384.22% |
